… in patients with post–myocardial infarction left ventricular dysfunction, in whom trandolapril
… However, in contrast to our study, just one kind of RAAS inhibitor was used in all these trials. …

… If you wish to reuse any or all of this article please use the link below … of placebo, valsartan
80 mg twice daily or valsartan 160 mg … monotherapy in the post-myocardial infarction setting. …

… treatment by baseline value interaction. Comparisons between valsartan and placebo were
made for all patients … by age, gender, race, and concurrent use of ACEI and BB. Between-…

… cardiovascular morbidity after myocardial infarction (MI) in patients with signs of heart failure
and/or left ventricular … resource use, costs, and quality of life in patients receiving valsartan, …

… Danshen has been used for the treatment of various diseases… For this reason we chose
valsartan as positive control in this … alleviate LAD-induced post-myocardial infarction remodeling. …

… to limit or prevent the progression to heart failure. The outcome of LV remodeling post-MI …
The dose used in the VALIANT Trial (80 mg/kg/day) was twice the dose used in the current …

… patients with left ventricular dysfunction and/or heart failure (HF) following MI were randomized
to captopril, valsartan … , eGFR, NYHA class and use of beta and calcium channel blockers …

… addition of valsartan at a dose of 75–85 mg, similar to the level used in the present study,
to … treatment prevents stroke, transient ischemic attack, angina pectoris, and heart failure.A …

… combination with sodium-glucose co-transporter 2 inhibitors or in post-myocardial infarction
HF. … , a wider and earlier use of S/V in the management of HF patients should be considered. …

… risk of cardiovascular death or heart failure admission in patients with myocardial infarction
(MI) and left ventricular systolic dysfunction (LVSD) combined with either heart failure (HF) or …